| 1 Adverse effects |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.1 At the end of 5 weeks treatment |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.08 [0.00, 1.31] |
| 2 Short‐term improvement in CTS symptoms (Levine) (3 months or less) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 At the end of 5 weeks treatment |
1 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
0.09 [‐0.14, 0.32] |
| 3 Short‐term improvement in CTS symptoms (VAS pain 100mm) (3 months or less) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 At the end of 5 weeks treatment |
1 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
9.63 [‐0.01, 19.27] |
| 4 Short‐term improvement in functional ability (functional status score) (3 months or less) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 At the end of 5 weeks treatment |
1 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
0.04 [‐0.18, 0.26] |
